Intercell

Vienna, Austria Founded: 1998 • Age: 28 yrs
Vaccines for infectious diseases, including antigens and adjuvants, were developed.
Request Access

About Intercell

Intercell is a company based in Vienna (Austria) founded in 1998 by Arunabh Varma.. Intercell has raised $78.62 million across 2 funding rounds from investors including Global Life Science Ventures. Intercell has completed 1 acquisition, including Iomai Corporation. Intercell operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.

  • Headquarter Vienna, Austria
  • Founders Arunabh Varma
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $78.62 M (USD)

    in 2 rounds

  • Latest Funding Round
    $44.98 M (USD), Series B

    Feb 23, 2011

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    N/A

    (Dec 17, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Intercell

Intercell has successfully raised a total of $78.62M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $44.98 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $45.0M
  • First Round

    (17 Jul 2003)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2011 Amount Series B - Intercell Valuation

investors

Jul, 2003 Amount Series A - Intercell Valuation Global Life Science Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Intercell

Intercell has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Life Science Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Early & late stage life sciences focused VC firm funding companies in the US and Europe
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Intercell

Intercell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Iomai Corporation. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Vaccines and immune stimulants are developed via needle-free transcutaneous immunization.
1997
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Intercell

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Intercell Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Intercell

Intercell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Clinical diagnostics and drug discovery for immune diseases are provided.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
domain founded_year HQ Location
Developer of immunotherapies for the treatment of infectious diseases and cancer
domain founded_year HQ Location
Developer of biologics to treat hepatitis B infection
domain founded_year HQ Location
Developer of computationally designed VLP vaccines for treating multiple infections
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Intercell

When was Intercell founded?

Intercell was founded in 1998 and raised its 1st funding round 5 years after it was founded.

Where is Intercell located?

Intercell is headquartered in Vienna, Austria.

Who is the current CEO of Intercell?

Arunabh Varma is the current CEO of Intercell. They have also founded this company.

Is Intercell a funded company?

Intercell is a funded company, having raised a total of $78.62M across 2 funding rounds to date. The company's 1st funding round was a Series A of $33.64M, raised on Jul 17, 2003.

What does Intercell do?

Founded in 1998 in Vienna, Austria, Intercell focused on biotechnology within the infectious disease sector. Vaccines, antigens, and adjuvants were developed for various applications, with a Japanese encephalitis vaccine already marketed. Operations centered on research and production until the 2012 acquisition by Vivalis for 174 million, after which the combined entity was renamed Valneva.

Who are the top competitors of Intercell?

Intercell's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

How many acquisitions has Intercell made?

Intercell has made 1 acquisition, including Iomai Corporation.

Who are Intercell's investors?

Intercell has 1 investor. Key investors include Global Life Science Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available